-
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-25 Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Antón, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Alexei A Grom
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in
-
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-25 A. Quinlivan, D. Neuen, D. Hansen, W. Stevens, L. Ross, N. Ferdowsi, S. M. Proudman, J. G. Walker, J. Sahhar, G-S. Ngian, D. Apostolopoulos, L. V. Host, G. Major, C. Basnayake, K. Morrisroe, M. Nikpour
To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence
-
Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-24 Katherine P. Liao, Pamela Rist, Jon Giles, Leah Santacroce, Margery A. Connelly, Robert J. Glynn, Paul Ridker, Ahmed Tawakol, Joan Bathon, Daniel H. Solomon
Treatments for rheumatoid arthritis (RA) are associated with complex changes in lipids and lipoproteins that may impact cardiovascular (CV) risk. The objective of this study was to examine lipid and lipoprotein changes associated with two common RA treatment strategies, triple therapy or tumor necrosis factor inhibitor (TNFi), and association with CV risk. In this secondary data analysis of the TARGET
-
Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-18 Javier Narváez, Elena Cañadillas, Iván Castellví, Juan José Alegre, Vanesa Vincens-Zygmunt, Guadalupe Bermudo, Paola Vidal-Montal, María Molina Molina, Joan Miquel Nolla
To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD). Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants
-
Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-15 Kenta Makabe, Hiroyuki Okada, Naohiro Tachibana, Hisatoshi Ishikura, Norihito Ito, Masaru Tanaka, Ryota Chijimatsu, Asuka Terashima, Fumiko Yano, Meiko Asaka, Dai Yanagihara, Shuji Taketomi, Takumi Matsumoto, Sakae Tanaka, Yasunori Omata, Taku Saito
Janus kinase (JAK) inhibitors, such as baricitinib, are widely used to treat rheumatoid arthritis (RA). Clinical studies show that baricitinib is more effective at reducing pain than other similar drugs. Here, we aimed to elucidate the molecular mechanisms underlying the pain relief conferred by baricitinib, using a mouse model of arthritis. We treated collagen antibody-induced arthritis (CAIA) model
-
Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-12 Cankut Çubuk, Rachel Lau, Pedro Cutillas, Vinothini Rajeeve, Christopher R. John, Anna E. A. Surace, Rebecca Hands, Liliane Fossati-Jimack, Myles J. Lewis, Costantino Pitzalis
Kinases are intracellular signalling mediators and key to sustaining the inflammatory process in rheumatoid arthritis (RA). Oral inhibitors of Janus Kinase family (JAKs) are widely used in RA, while inhibitors of other kinase families e.g. phosphoinositide 3-kinase (PI3K) are under development. Most current biomarker platforms quantify mRNA/protein levels, but give no direct information on whether
-
The integrin CD11b inhibits MSU-induced NLRP3 inflammasome activation in macrophages and protects mice against MSU-induced joint inflammation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-11 Driss Ehirchiou, Ilaria Bernabei, Vishnuprabu Durairaj Pandian, Sonia Nasi, Veronique Chobaz, Mariela Castelblanco, Alexander So, Fabio Martinon, Xiaoyun Li, Hans Acha-Orbea, Thomas Hugle, Li Zhang, Nathalie Busso
In gout, monosodium urate crystals are taken up by macrophages, triggering the activation of the NLRP3 inflammasome and the maturation of IL-1β. This study aimed to investigate the role of integrin CD11b in inflammasome activation in macrophages stimulated by MSU. BMDM from WT and CD11b KO mice were stimulated in vitro with MSU crystals. Cellular supernatants were collected to assess the expression
-
Development of primary osteoarthritis during aging in genetically diverse UM-HET3 mice Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-08 Sher Bahadur Poudel, Ryan R. Ruff, Gozde Yildirim, Richard A. Miller, David E. Harrison, Randy Strong, Thorsten Kirsch, Shoshana Yakar
Primary osteoarthritis (OA) occurs without identifiable underlying causes such as previous injuries or specific medical conditions. Age is a major contributing factor to OA, and as one ages, various joint tissues undergo gradual change, including degeneration of the articular cartilage, alterations in subchondral bone (SCB) morphology, and inflammation of the synovium. We investigated the prevalence
-
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-06 Stanley Cohen, Jean S. Beebe, Vishala Chindalore, Shunjie Guan, Mina Hassan-Zahraee, Madhurima Saxena, Li Xi, Craig Hyde, Sarita Koride, Robert Levin, Shannon Lubaczewski, Mikhail Salganik, Abigail Sloan, Erin Stevens, Elena Peeva, Michael S. Vincent, David A. Martin, Myron Chu
The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5) that potentially depletes B cells, follicular T helper (Tfh) cells, and circulating Tfh-like (cTfh) cells, in patients with systemic lupus erythematosus (SLE) and rheumatoid
-
Single-cell and genome-wide Mendelian randomization identifies causative genes for gout Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-03 Yubiao Yang, Ping Hu, Qinnan Zhang, Boyuan Ma, Jinyu Chen, Bitao Wang, Jun Ma, Derong Liu, Jian Hao, Xianhu Zhou
Gout is a prevalent manifestation of metabolic osteoarthritis induced by elevated blood uric acid levels. The purpose of this study was to investigate the mechanisms of gene expression regulation in gout disease and elucidate its pathogenesis. The study integrated gout genome-wide association study (GWAS) data, single-cell transcriptomics (scRNA-seq), expression quantitative trait loci (eQTL), and
-
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-05 Javier Loricera, Toluwalase Tofade, Diana Prieto-Peña, Susana Romero-Yuste, Eugenio de Miguel, Anne Riveros-Frutos, Iván Ferraz-Amaro, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narváez, Eva Galíndez-Agirregoikoa, Ismael González-Fernández, Ana Urruticoechea-Arana, Ángel Ramos-Calvo, Fernando López-Gutiérrez, Santos Castañeda, Sebastian Unizony, Ricardo Blanco
A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative. We evaluated the effectiveness of JAKi in relapsing
-
Exploration of the combined role of immune checkpoints and immune cells in the diagnosis and treatment of ankylosing spondylitis: a preliminary study immune checkpoints in ankylosing spondylitis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-06-04 Feihong Huang, Zhiping Su, Yibin Huang, Yuxiang Huang, Chengyu Zhou, Sitan Feng, Xiong Qin, Xi Xie, Chong Liu, Chaojie Yu
Immune checkpoints have emerged as promising therapeutic targets for autoimmune diseases. However, the specific roles of immune checkpoints in the pathophysiology of ankylosing spondylitis (AS) remain unclear. Hip ligament samples were obtained from two patient groups: those with AS and femoral head deformity, and those with femoral head necrosis but without AS, undergoing hip arthroplasty. Label-Free
-
Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-31 Xiang-Yu Han, Zhi-Ying Li, Ming-Hui Zhao, Mark A. Little, Min Chen
It has been reported that in western countries malignancy risk was higher in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) compared with that in the general population. In the current study, we investigated the incidence, spectrum and risk factors of malignancy in Chinese AAV patients. AAV patients diagnosed from 1995 to 2021 in Peking University First Hospital
-
Predictive models of radiographic progression and pain progression in patients with knee osteoarthritis: data from the FNIH OA biomarkers consortium project Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-30 Xiaoyu Li, Chunpu Li, Peng Zhang
The progression of knee osteoarthritis (OA) can be defined as either radiographic progression or pain progression. This study aimed to construct models to predict radiographic progression and pain progression in patients with knee OA. We retrieved data from the FNIH OA Biomarkers Consortium project, a nested case-control study. A total of 600 subjects with mild to moderate OA (Kellgren-Lawrence grade
-
MiR-653-5p drives osteoarthritis pathogenesis by modulating chondrocyte senescence Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-29 Yucheng Lin, Lu Zhang, Mingliang Ji, Sinuo Shen, Yuzhi Chen, Shichao Wu, Xiaotao Wu, Nancy Q. Liu, Jun Lu
Due to the unclear pathogenesis of osteoarthritis (OA), effective treatment for this ailment is presently unavailable. Accumulating evidence points to chondrocyte senescence as a key driver in OA development. This study aims to identify OA-specific microRNAs (miRNAs) targeting chondrocyte senescence to alleviate OA progression. We screened and identified miRNAs differentially expressed in OA and normal
-
Microstructural changes of the white matter in systemic lupus erythematosus patients without neuropsychiatric symptoms: a multi-shell diffusion imaging study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-28 Wenjun Hu, Ziru Qiu, Qin Huang, Yuhao Lin, Jiaying Mo, Linhui Wang, Jingyi Wang, Kan Deng, Yanqiu Feng, Xinyuan Zhang, Xiangliang Tan
Diffusion kurtosis imaging (DKI) and neurite orientation dispersion and density imaging (NODDI) provide more comprehensive and informative perspective on microstructural alterations of cerebral white matter (WM) than single-shell diffusion tensor imaging (DTI), especially in the detection of crossing fiber. However, studies on systemic lupus erythematosus patients without neuropsychiatric symptoms
-
The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Yutong Li, Junyan Qian, Xingbei Dong, Jiuliang Zhao, Qian Wang, Yanhong Wang, Xiaofeng Zeng, Zhuang Tian, Mengtao Li
The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guideline has recently revised the hemodynamic definition of pulmonary arterial hypertension. However, there is currently limited research on the prognosis and treatment of system lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) patients that have been reclassified by the new hemodynamic definition
-
Epidemiological trends in psoriatic arthritis: a comprehensive population-based study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Amir Haddad, Perach Chen Elkayam, Nili Stein, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman
Psoriatic arthritis (PsA) is a chronic, potentially debilitating inflammatory arthritis often associated with psoriasis. Understanding the epidemiology of PsA across diverse populations can provide valuable insights into its global burden and the role of genetic and environmental factors. This study aimed to estimate PsA’s temporal trends, prevalence, and incidence, while assessing variations in age
-
Investigating protease-mediated peptides of inflammation and tissue remodeling as biomarkers associated with flares in psoriatic arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-27 Solveig Skovlund Groen, Signe Holm Nielsen, Anne Christine Bay-Jensen, Mozhgan Rasti, Darshini Ganatra, Katerina Oikonomopoulou, Vinod Chandran
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. PsA disease involves flares, which are associated with increased joint inflammation and tissue remodeling. There is a need for identifying biomarkers related to PsA disease activity and flares to improve the management of PsA patients and decrease flares. The tissue turnover imbalance that occurs during the inflammatory
-
Two-year post-distraction cartilage-related structural improvement is accompanied by increased serum full-length SIRT1 Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-24 Miya Marco, Mylène Jansen, Goran van der Weiden, Eli Reich, Yonathan H. Maatuf, Simon C. Mastbergen, Mona Dvir-Ginzberg
Previously, fragments from Sirtuin 1 (SIRT1) were identified in preclinical and clinical samples to display an increase in serum levels for N-terminal (NT) SIRT1 vs. C-terminal (CT) SIRT1, indicative of early signs of OA. Here we tested NT/CT SIRT1 levels as well as a novel formulated sandwich assay to simultaneously detect both domains of SIRT1 in a manner that may inform us about the levels of full-length
-
Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-24 Victoria Navarro-Compán, Atul Deodhar, Rachid Bahiri, Andrew G. Bushmakin, Joseph C. Cappelleri, Jihane Rammaoui
Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. This post hoc analysis used phase 3 trial data from patients with AS receiving tofacitinib 5 mg twice daily or placebo to week (W)16; all patients received open-label tofacitinib W16–48. Outcomes: nocturnal pain;
-
Causal relationship between rheumatoid arthritis and bronchiectasis: a bidirectional mendelian randomization study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-23 Zehu Chen, Xuegang Li, Honglei Shi, Yiying Huang, Jing Liu
Epidemiological observational studies have elucidated a correlation between rheumatoid arthritis (RA) and bronchiectasis. However, the causal nature of this association remains ambiguous. To clarify this potential causal linkage, we conducted a two-sample Mendelian randomization (MR) analysis to explore the bidirectional causality between RA and bronchiectasis. Summary statistics for RA and bronchiectasis
-
Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-23 Hongyan Qian, Chaoqiong Deng, Shiju Chen, Xinwei Zhang, Yan He, Jingying Lan, Aodi Wang, Guixiu Shi, Yuan Liu
Fibroblast-like synoviocytes (FLSs) play a central role in RA pathogenesis and are the main cellular component in the inflamed synovium of patients with rheumatoid arthritis (RA). FLSs are emerging as promising new therapeutic targets in RA. However, fibroblasts perform many essential functions that are required for sustaining tissue homeostasis. Direct targeting of general fibroblast markers on FLSs
-
Dystrophic calcinosis: structural and morphological composition, and evaluation of ethylenediaminetetraacetic acid (‘EDTA’) for potential local treatment Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-22 Phillip Lee, Lorraine Green, Bartosz Marzec, Fiona Meldrum, Francesco Del Galdo, Begonya Alcacer-Pitarch
To perform a detailed morphological analysis of the inorganic portion of two different clinical presentations of calcium-based deposits retrieved from subjects with SSc and identify a chemical dissolution of these deposits suitable for clinical use. Chemical analysis using Fourier Transform IR spectroscopy (‘FTIR’), Raman microscopy, Powder X-Ray Diffraction (‘PXRD’), and Transmission Electron Microscopy
-
The role of M1/M2 macrophage polarization in primary Sjogren’s syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-14 Xiaochan Chen, Linjiang Zhu, Huaxiang Wu
The purpose of this study was to investigate the role of macrophage polarization in the pathogenesis of primary Sjogren’s syndrome (pSS). Peripheral venous blood samples were collected from 30 patients with pSS and 30 healthy controls. Minor salivary gland samples were abtainted from 10 of these patients and 10 non-pSS controls whose minor salivary gland didn’t fulfill the classification criteria for
-
Identification and verification of a novel signature that combines cuproptosis-related genes with ferroptosis-related genes in osteoarthritis using bioinformatics analysis and experimental validation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-13 Baoqiang He, Yehui Liao, Minghao Tian, Chao Tang, Qiang Tang, Fei Ma, Wenyang Zhou, Yebo Leng, Dejun Zhong
Exploring the pathogenesis of osteoarthritis (OA) is important for its prevention, diagnosis, and treatment. Therefore, we aimed to construct novel signature genes (c-FRGs) combining cuproptosis-related genes (CRGs) with ferroptosis-related genes (FRGs) to explore the pathogenesis of OA and aid in its treatment. Differentially expressed c-FRGs (c-FDEGs) were obtained using R software. Enrichment analysis
-
Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-13 Frank Qingyun Wang, Li Shao, Xiao Dang, Yong-Fei Wang, Shuxiong Chen, Zhongyi Liu, Yujing Mao, Yuping Jiang, Fei Hou, Xianghua Guo, Jian Li, Lili Zhang, Yuting Sang, Xuan Zhao, Ruirui Ma, Kai Zhang, Yanfang Zhang, Jing Yang, Xiwu Wen, Jiong Liu, Wei Wei, Chuanpeng Zhang, Weiyang Li, Xiao Qin, Yao Lei, Hong Feng, Xingtian Yang, Chun Hing She, Caicai Zhang, Huidong Su, Xinxin Chen, Jing Yang, Yu Lung
This study aims to elucidate the transcriptomic signatures and dysregulated pathways in patients with Systemic Lupus Erythematosus (SLE), with a particular focus on those persisting during disease remission. We conducted bulk RNA-sequencing of peripheral blood mononuclear cells (PBMCs) from a well-defined cohort comprising 26 remission patients meeting the Low Lupus Disease Activity State (LLDAS) criteria
-
Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-10 Shiheng Wang, Wanling Ning, Hanqing Tang, Chaochao Mu, Xiaosong Huang
Targeted small-molecule drugs in the treatment of systemic lupus erythematosus (SLE) have attracted increasing attention from clinical investigators. However, there is still a lack of evidence on the difference in the efficacy and safety of different targeted small-molecule drugs. Therefore, this study was conducted to assess the efficacy and safety of different targeted small-molecule drugs for SLE
-
Early identification of macrophage activation syndrome secondary to systemic lupus erythematosus with machine learning Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-09 Wenxun Lin, Xi Xie, Zhijun Luo, Xiaoqi Chen, Heng Cao, Xun Fang, You Song, Xujing Yuan, Xiaojing Liu, Rong Du
The macrophage activation syndrome (MAS) secondary to systemic lupus erythematosus (SLE) is a severe and life-threatening complication. Early diagnosis of MAS is particularly challenging. In this study, machine learning models and diagnostic scoring card were developed to aid in clinical decision-making using clinical characteristics. We retrospectively collected clinical data from 188 patients with
-
Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-07 Julia Lehmann, Stavros Giaglis, Diego Kyburz, Douglas Daoudlarian, Ulrich A. Walker
Neutrophil extracellular trap formation and cell-free DNA (cfDNA) contribute to the inflammation in rheumatoid arthritis (RA), but it is unknown if mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) is more abundant in the circulation. It is unclear if DNA concentration measurements may assist in clinical decision-making. This single-center prospective observational study collected plasma from consecutive
-
Deficiency of histone deacetylases 3 in macrophage alleviates monosodium urate crystals-induced gouty inflammation in mice Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-06 Qi-Bin Yang, Meng-Yun Zhang, Liu Yang, Jie Wang, Qing-Sheng Mi, Jing-Guo Zhou
Gout is caused by monosodium urate (MSU) crystals deposition to trigger immune response. A recent study suggested that inhibition of Class I Histone deacetylases (HDACs) can significantly reduce MSU crystals-induced inflammation. However, which one of HDACs members in response to MSU crystals was still unknown. Here, we investigated the roles of HDAC3 in MSU crystals-induced gouty inflammation. Macrophage
-
Rheumatoid arthritis disease activity significantly impacts on the severity of interstitial lung disease Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-04 Yuhei Ito, Yasutaka Ichikawa, Shuichi Murashima, Hajime Sakuma, Ayako Nakajima
Rheumatoid arthritis (RA) related interstitial lung disease (ILD) impacts on the treatment strategy and its prognosis in patients with RA. However, the relationship between RA disease activity and the severity of comorbid ILD has not been fully investigated. This study aimed to investigate the impact of RA disease activity on the severity of comorbid ILD in detail based on currently established visual
-
Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-03 Takumi Hasegawa, Akira Utsunomiya, Takenao Chino, Hiroshi Kasamatsu, Tomomi Shimizu, Takashi Matsushita, Takashi Obara, Naoto Ishii, Hideaki Ogasawara, Wataru Ikeda, Toshio Imai, Noritaka Oyama, Minoru Hasegawa
Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular injury and inflammation, followed by excessive fibrosis of the skin and other internal organs, including the lungs. CX3CL1 (fractalkine), a chemokine expressed on endothelial cells, supports the migration of macrophages and T cells that express its specific receptor CX3CR1 into targeted tissues. We previously reported that
-
Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-05-03 Tomoya Watanabe, Yasushi Ototake, Asami Akita, Mao Suzuki, Miwa Kanaoka, Jun Tamura, Yusuke Saigusa, Yukie Yamaguchi
Anti-SS-A/Ro antibody (anti-SSA), the diagnostic marker of Sjögren’s syndrome (SS), is often detected in systemic sclerosis (SSc). Some patients are diagnosed with SSc/SS overlap syndromes, while there are anti-SSA-positive SSc cases without SS. In this study, we investigated the clinical characteristics of SSc with anti-SSA and clarified the clinical impact of this antibody in SSc. A retrospective
-
Thyroid hormone induces ossification and terminal maturation in a preserved OA cartilage biomimetic model Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-25 N. M. Korthagen, E. Houtman, I. Boone, R. Coutinho de Almeida, K. Sivasubramaniyan, R. Mahdad, R. G. H. H Nelissen, Y. F. M. Ramos, M. A Tessari, I. Meulenbelt
To characterize aspects of triiodothyronine (T3) induced chondrocyte terminal maturation within the molecular osteoarthritis pathophysiology using the previously established T3 human ex vivo osteochondral explant model. RNA-sequencing was performed on explant cartilage obtained from OA patients (n = 8), that was cultured ex vivo with or without T3 (10 ng/ml), and main findings were validated using
-
Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-25 Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha
We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes
-
Retraction Note: Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-19 Yanfeng Wu, Mingliang Ren, Rui Yang, Xinjun Liang, Yuanchen Ma, Yong Tang, Lin Huang, Jichao Ye, Keng Chen, Peng Wang, Huiyong Shen
Retraction Note: Arthritis Res Ther 13, R29 (2011) https://doi.org/10.1186/ar3257 The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding highly similar images in Fig. 1A-C, specifically: Panels A2 and C2 appear highly similar, with 180 degree rotation. Panels A3 and C3 appear to overlap. Panels B4 and C4 appear to overlap. The authors have stated that incorrect
-
Osteoarthritis and hypertension: observational and Mendelian randomization analyses Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-17 Zhi-Jie Yang, Yuan Liu, Yan-Li Liu, Bin Qi, Xin Yuan, Wan-Xin Shi, Liu Miao
The association between osteoarthritis (OA) and hypertension is a subject of ongoing debate in observational research, and the underlying causal relationship between them remains elusive. This study retrospectively included 24,871 participants in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2020. Weighted logistic regression was performed to investigate the connection
-
Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-17 Zento Yamada, Sei Muraoka, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Takahiko Sugihara, Toshihiro Nanki
We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients. In this open-label, prospective, observational study, patients were stratified into four groups: younger (20–64 years old) and older (≥ 65 years) patients taking ABT (AY and AO) and conventional synthetic
-
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-12 Emily E. Holladay, Amy S. Mudano, Fenglong Xie, Jingyi Zhang, Ted R. Mikuls, Brian LaMoreaux, Lissa Padnick-Silver, Jeffrey R. Curtis
Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation. We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry
-
Deregulation in adult IgA vasculitis skin as the basis for the discovery of novel serum biomarkers Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-12 Matija Bajželj, Matjaž Hladnik, Rok Blagus, Vesna Jurčić, Ana Markež, Tanya Deniz Toluay, Snežna Sodin-Šemrl, Alojzija Hočevar, Katja Lakota
Immunoglobulin A vasculitis (IgAV) in adults has a variable disease course, with patients often developing gastrointestinal and renal involvement and thus contributing to higher mortality. Due to understudied molecular mechanisms in IgAV currently used biomarkers for IgAV visceral involvement are largely lacking. Our aim was to search for potential serum biomarkers based on the skin transcriptomic
-
Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-12 Shuping Wei, Haiyun Shen, Yidan Zhang, Chunrui Liu, Shoushan Li, Jing Yao, Zhibin Jin, Hongliang Yu
We attempted to identify abnormal immune cell components and signaling pathways in lupus nephritis (LN) and to identify potential therapeutic targets. Differentially expressed genes (DEGs) between LN and normal kidney tissues were identified from bulk transcriptome data, and functional annotation was performed. The phenotypic changes in macrophages and aberrant intercellular signaling communications
-
Usability and preliminary effectiveness of an app-based physical activity and education program for people with hip or knee osteoarthritis – a pilot randomized controlled trial Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-10 F. Weber, C. Kloek, S. Stuhrmann, Y. Blum, C. Grüneberg, C. Veenhof
Hip and knee osteoarthritis (OA) are highly prevalent worldwide. The guidelines recommend physical activity and education as the core treatments for osteoarthritis. Digital health has the potential to engage people in physical activity and disease management. Therefore, we conducted a pilot trial to assess the usability and preliminary effectiveness of an app-based physical activity and education program
-
Anxiety and depression symptoms in adolescents and young adults with juvenile idiopathic arthritis: results of an outpatient screening Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-10 Florian Milatz, Jens Klotsche, Martina Niewerth, Claudia Sengler, Daniel Windschall, Tilmann Kallinich, Frank Dressler, Ralf Trauzeddel, Reinhard W. Holl, Ivan Foeldvari, Normi Brück, Svenja Temming, Toni Hospach, Petra Warschburger, Rainer Berendes, Gabriele Erbis, Jasmin B. Kuemmerle-Deschner, Frank Weller-Heinemann, Johannes-Peter Haas, Annabel S. Müller-Stierlin, Agnes Mutter, Thomas Meissner,
Previous studies have shown that growing up with rheumatic conditions can fuel dissatisfaction and psychological distress, which in turn affects disease self-management and treatment adherence. Primary objective of this study was to estimate the prevalence of anxiety and depression symptoms in adolescents and young adults (AYA) with juvenile idiopathic arthritis (JIA) and to identify correlates of
-
Correction: Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-10 Stefano Soldano, Vanessa Smith, Paola Montagna, Emanuele Gotelli, Rosanna Campitiello, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Andrea Cere, Maurizio Cutolo
Correction: Arthritis Res Ther 26, 74 (2024) https://doi.org/10.1186/s13075-024-03308-7 Following publication of the original article [1], the authors reported that the equal contribution statement was missing. The following statement has been added “Stefano Soldano and Vanessa Smith contributed equally to the manuscript as first authors.” The original article [1] has been updated. Soldano S, Smith
-
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-08 Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen
Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS). This study used the JIR cohort, a multicentre international registry created in 2013 to collect data on patients with juvenile inflammatory
-
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-03 Corrado Campochiaro, Nicola Farina, Giacomo De Luca, Veronica Batani, Giorgia Trignani, Davide Vignale, Anna Palmisano, Marco Matucci-Cerinic, Lorenzo Dagna
Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolate mofetil (MMF) and rituximab (RTX) may be effective in controlling difficult-to-treat patients. Our aim was to further explore the efficacy and safety of this combined approach in patients with
-
Specific isoforms of the ubiquitin ligase gene WWP2 are targets of osteoarthritis genetic risk via a differentially methylated DNA sequence Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-04-03 Jack B. Roberts, Olivia L.G. Boldvig, Guillaume Aubourg, S. Tanishq Kanchenapally, David J. Deehan, Sarah J. Rice, John Loughlin
Transitioning from a genetic association signal to an effector gene and a targetable molecular mechanism requires the application of functional fine-mapping tools such as reporter assays and genome editing. In this report, we undertook such studies on the osteoarthritis (OA) risk that is marked by single nucleotide polymorphism (SNP) rs34195470 (A > G). The OA risk-conferring G allele of this SNP associates
-
Peptidoglycan in osteoarthritis synovial tissue is associated with joint inflammation Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-27 Meaghan N Holub, Amanda Wahhab, Joseph R Rouse, Rebecca Danner, Lauren G Hackner, Christine B Duris, Mecaila E McClune, Jules M Dressler, Klemen Strle, Brandon L Jutras, Adam I Edelstein, Robert B Lochhead
Peptidoglycan (PG) is an arthritogenic bacterial cell wall component whose role in human osteoarthritis is poorly understood. The purpose of this study was to determine if PG is present in synovial tissue of osteoarthritis patients at the time of primary total knee arthroplasty (TKA), and if its presence is associated with inflammation and patient reported outcomes. Intraoperative synovial tissue and
-
Deficiency of peripheral CLA+ Tregs and clinical relevance in Behcet’s syndrome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-21 Jiachen Li, Feng Sun, Danxue Zhu, Yuke Hou, Gong Cheng, Ping Wang, Xu Jin, Wenyan Zhou, Xiaolin Sun, Zhanguo Li, Tian Liu
Autoimmune responses have been suggested to involvement in patients with Behcet’s syndrome (BS). There has been growing attention towards the roles of cutaneous lymphocyte antigen (CLA)+ regular T cells (Tregs) in autoimmune diseases. The role of CLA+ Tregs in BS is still uncertain. This study aims to clarify the impact of CLA+ Tregs on BS. We collected peripheral blood from a total of 107 patients
-
Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-20 Ann-Christin Pecher, Reinhild Klein, Ina Koetter, Marieke Wagner, Wichard Vogel, Stefan Wirths, Claudia Lengerke, Joerg Christoph Henes
Treatment with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (aHSCT) is an intensive treatment option for patients with severe forms of systemic sclerosis (SSc). Even though associated with a high treatment related mortality, the results in this high-risk population are generally favourable. The knowledge on the potential mechanism of action of this therapy and
-
Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-20 Stefano Soldano, Vanessa Smith, Paola Montagna, Emanuele Gotelli, Rosanna Campitiello, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Andrea Cere, Maurizio Cutolo
Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by vasculopathy and progressive fibrosis of skin and several internal organs, including lungs. Macrophages are the main cells involved in the immune-inflammatory damage of skin and lungs, and alternatively activated (M2) macrophages seem to have a profibrotic role through the release of profibrotic cytokines (IL10) and
-
Targeting STAT6-mediated synovial macrophage activation improves pain in experimental knee osteoarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-20 Garth Blackler, Yue Lai-Zhao, Joseph Klapak, Holly T. Philpott, Kyle K. Pitchers, Andrew R. Maher, Benoit Fiset, Logan A. Walsh, Elizabeth R. Gillies, C. Thomas Appleton
Pain from osteoarthritis (OA) is one of the top causes of disability worldwide, but effective treatment is lacking. Nociceptive factors are released by activated synovial macrophages in OA, but depletion of synovial macrophages paradoxically worsens inflammation and tissue damage in previous studies. Rather than depleting macrophages, we hypothesized that inhibiting macrophage activation may improve
-
The prevalence of sarcopenia in spondyloarthritis patients: a meta-analysis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-16 Jiawen Hu, Yiwen Wang, Xiaojian Ji, Yinan Zhang, Kunpeng Li, Feng Huang
Spondyloarthritis (SpA) is a chronic inflammatory disorder that affects sacroiliac joints and spine, resulting in substantial disability. Sarcopenia, characterized by the loss of muscle mass and function, is a prevalent comorbidity in various chronic diseases. However, the exact prevalence of sarcopenia in SpA patients remains uncertain. The objective of this study is to conduct a systematic review
-
TfR1 mediated iron metabolism dysfunction as a potential therapeutic target for osteoarthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-16 Wenchao Wang, Zhenkai Ma, Xuemin Feng, Jiabin Ren, Shengyao Sun, Yuandong Shao, Weimin Zhang, Xiaoxia Yang, Jiaming Zhang, Xingzhi Jing
Transferrin receptor-1 (TfR1) plays important roles in controlling cellular iron levels, but its role in OA pathology is unknown. Herein we aim to investigate the role of TfR1 in OA progression and its underlying mechanisms. TfR1 expression in cartilage during OA development were examined both in vivo and in vitro. Then IL-1β was used to induce chondrocytes degeneration in vitro and TfR1 siRNA was
-
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-16 Sabrina Pollastro, Anne Musters, Giulia Balzaretti, Ilse Niewold, Barbera van Schaik, Signe Hässler, Catharina M. Verhoef, Marc Pallardy, Antoine van Kampen, Xavier Mariette, Niek de Vries
Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself. The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage
-
Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-14 Mojca Zajc Avramovič, Nataša Toplak, Gašper Markelj, Nina Emeršič, Tadej Avčin
To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children’s Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular
-
Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-14 Lisa Christ, Seraphina Kissling, Axel Finckh, Benjamin A. Fisher, Sabine Adler, Britta Maurer, Burkhard Möller, Florian Kollert
To investigate the clinical phenotype and treatment response in patients with rheumatoid arthritis (RA) with and without concomitant Sjögren’s disease (SjD). In this observational cohort study, patients with RA from the Swiss Clinical Quality Management in Rheumatic Diseases registry were categorised according to the presence or absence of SjD. To assess treatment effectiveness, drug retention of tumor
-
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-12 Jun Li, Liying Peng, Lijun Wu, Yufang Ding, Xinwang Duan, Jian Xu, Wei Wei, Zhen Chen, Cheng Zhao, Min Yang, Nan Jiang, Shangzhu Zhang, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Yan Zhao, Jiuliang Zhao
To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 109/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected
-
Streamlined, single-step non-viral CRISPR-Cas9 knockout strategy enhances gene editing efficiency in primary human chondrocyte populations Arthritis Res. Ther. (IF 4.4) Pub Date : 2024-03-11 Simone Ponta, Angela Bonato, Philipp Neidenbach, Valentino F. Bruhin, Alexis Laurent, Lee Ann Applegate, Marcy Zenobi-Wong, Goncalo Barreto
CRISPR-Cas9-based genome engineering represents a powerful therapeutic tool for cartilage tissue engineering and for understanding molecular pathways driving cartilage diseases. However, primary chondrocytes are difficult to transfect and rapidly dedifferentiate during monolayer (2D) cell culture, making the lengthy expansion of a single-cell-derived edited clonal population not feasible. For this